Anagram Therapeutics initiates Phase 2 trial for ANG003 in exocrine pancreatic insufficiency
Anagram Therapeutics is conducting Phase 2 study to evaluate the safety and efficacy of ANG003 for exocrine pancreatic insufficiency.
Asset / Drug
Drug and asset intelligence for ANG003 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Enzyme Replacement Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.